By: Benzinga
January 17, 2013 at 13:12 PM EST
UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking For Better Entry
Credit Suisse initiated coverage on Alkermes (NASDAQ: ALKS ) with a Neutral rating and a $24.00 price target. Credit Suisse said, "ALKS has an attractive long-term story, but we initiate at Neutral given the potential for a better entry point. Considering ALKS is up 21% YTD (Biotech up 7%, Pharma
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here